NO20052955L - Treatment of Huntington's disease with EPA - Google Patents

Treatment of Huntington's disease with EPA

Info

Publication number
NO20052955L
NO20052955L NO20052955A NO20052955A NO20052955L NO 20052955 L NO20052955 L NO 20052955L NO 20052955 A NO20052955 A NO 20052955A NO 20052955 A NO20052955 A NO 20052955A NO 20052955 L NO20052955 L NO 20052955L
Authority
NO
Norway
Prior art keywords
huntington
epa
disease
treatment
respond
Prior art date
Application number
NO20052955A
Other languages
Norwegian (no)
Inventor
David Frederick Horrobin
Original Assignee
Amarin Neuroscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amarin Neuroscience Ltd filed Critical Amarin Neuroscience Ltd
Publication of NO20052955L publication Critical patent/NO20052955L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Analysis of the huntington gene provides a method for identifying patients likely to respond to treatment of Huntington's disease with eicosapentaenoic acid, EPA.
NO20052955A 2002-12-02 2005-06-16 Treatment of Huntington's disease with EPA NO20052955L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0228079.0A GB0228079D0 (en) 2002-12-02 2002-12-02 Huntington's Disease
PCT/GB2003/005131 WO2004050913A1 (en) 2002-12-02 2003-11-26 Treatment of huntington’s disease with epa

Publications (1)

Publication Number Publication Date
NO20052955L true NO20052955L (en) 2005-06-16

Family

ID=9948921

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052955A NO20052955L (en) 2002-12-02 2005-06-16 Treatment of Huntington's disease with EPA

Country Status (28)

Country Link
US (2) US20070148643A1 (en)
EP (1) EP1567667B1 (en)
JP (1) JP2006507833A (en)
KR (1) KR20050086895A (en)
CN (1) CN1717497A (en)
AT (1) ATE411399T1 (en)
AU (1) AU2003285519A1 (en)
BR (1) BR0316969A (en)
CA (1) CA2506727A1 (en)
CY (1) CY1108730T1 (en)
DE (1) DE60324180D1 (en)
DK (1) DK1567667T3 (en)
ES (1) ES2315543T3 (en)
GB (1) GB0228079D0 (en)
HR (1) HRP20050493A2 (en)
IS (1) IS7842A (en)
MX (1) MXPA05005908A (en)
MY (1) MY138759A (en)
NO (1) NO20052955L (en)
NZ (1) NZ539989A (en)
PL (1) PL376101A1 (en)
PT (1) PT1567667E (en)
RU (1) RU2332209C2 (en)
SI (1) SI1567667T1 (en)
TW (1) TWI306120B (en)
UA (1) UA86582C2 (en)
WO (1) WO2004050913A1 (en)
ZA (1) ZA200504003B (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1713463A4 (en) * 2004-01-19 2009-03-18 Martek Biosciences Corp Reelin deficiency or dysfunction and methods related thereto
WO2007123391A1 (en) 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
EP1857548A1 (en) 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
JP6047270B2 (en) 2006-08-11 2016-12-21 バイオマリン テクノロジーズ ベー．フェー． Methods and means for treating genetic disorders associated with instability of DNA repeats
CN103212085A (en) 2007-07-12 2013-07-24 普罗森那技术公司 Molecules for targeting compounds to various selected organs or tissues
CA2693742A1 (en) 2007-07-12 2009-01-15 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs, tissues or tumor cells
EP2203173B1 (en) 2007-10-26 2015-12-23 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
WO2009099326A1 (en) 2008-02-08 2009-08-13 Prosensa Holding Bv Methods and means for treating dna repeat instability associated genetic disorders
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
EP4137128A1 (en) 2008-09-02 2023-02-22 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and a statin, and methods of using same
ES2768091T3 (en) 2009-02-10 2020-06-19 Amarin Pharmaceuticals Ie Ltd Use of Eicosapentaenoic Acid Ethyl Ester to Treat Hypertriglyceridemia
EP2421971B1 (en) 2009-04-24 2016-07-06 BioMarin Technologies B.V. Oligonucleotide comprising an inosine for treating dmd
NZ720946A (en) 2009-04-29 2017-09-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MX350088B (en) 2009-04-29 2017-08-25 Amarin Pharma Inc Stable pharmaceutical composition and methods of using same.
CN108096209A (en) 2009-06-15 2018-06-01 阿马里纳制药公司 Triglycerides, composition and method without increasing LDL-C levels are reduced in the object of associated Statins therapy
US20110071176A1 (en) 2009-09-23 2011-03-24 Amarin Pharma, Inc. Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
EP2516647B1 (en) 2009-12-24 2016-12-14 BioMarin Technologies B.V. Molecule for treating an inflammatory disorder
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ712068A (en) 2010-11-29 2017-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
ES2891473T3 (en) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Compositions and methods for reducing high sensitivity levels (hs-CRP) in a subject
CN118581086A (en) 2012-01-27 2024-09-03 比奥马林技术公司 RNA regulatory oligonucleotides with improved properties for the treatment of Duchenne muscular dystrophy and Becker muscular dystrophy
CA3067012C (en) 2012-06-29 2021-10-05 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
MA51766A (en) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ie Ltd METHODS OF REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN A SUBJECT
BR112022009189A2 (en) 2019-11-12 2022-07-26 Amarin Pharmaceuticals Ie Ltd METHODS TO REDUCE THE RISK OF CARDIOVASCULAR EVENT IN A SUBJECT WITH ATRIAL FIBRILLATION AND/OR ATRIAL PALPITATION
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6A (en) * 1836-08-10 Thomas Blanchard Machine for forming end pieces of plank blocks for ships
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
CA2116280A1 (en) * 1993-03-05 1994-09-06 Marcy E. Macdonald Huntingtin dna, protein and uses thereof
CA2094169A1 (en) * 1993-04-16 1994-10-17 Rick E. Preddie Agents for the prevention and cure of huntington disease in humans: cdna, precursor polypeptide hormone and active hormone reconstructed from the antisense strand of the huntingtondisease gene, "huntingtin"
CA2216057A1 (en) * 1997-09-19 1999-03-19 Ridha Joober Polymorphic cag repeat-containing gene, diagnosis of psychiatric diseases and therapeutic uses thereof
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
JP2003510349A (en) * 1999-10-07 2003-03-18 ノヴァ−ニューロン インコーポレーテッド Genes required for striatal function, their use, and compounds for regulating them

Also Published As

Publication number Publication date
RU2332209C2 (en) 2008-08-27
BR0316969A (en) 2005-10-25
EP1567667A1 (en) 2005-08-31
SI1567667T1 (en) 2009-04-30
TWI306120B (en) 2009-02-11
RU2005115536A (en) 2006-01-27
CN1717497A (en) 2006-01-04
CA2506727A1 (en) 2004-06-17
GB0228079D0 (en) 2003-01-08
JP2006507833A (en) 2006-03-09
ZA200504003B (en) 2007-01-31
US20070148643A1 (en) 2007-06-28
TW200418993A (en) 2004-10-01
IS7842A (en) 2005-05-12
ATE411399T1 (en) 2008-10-15
AU2003285519A1 (en) 2004-06-23
MXPA05005908A (en) 2005-12-12
CY1108730T1 (en) 2014-04-09
WO2004050913A1 (en) 2004-06-17
US20090270504A1 (en) 2009-10-29
ES2315543T3 (en) 2009-04-01
NZ539989A (en) 2006-11-30
MY138759A (en) 2009-07-31
KR20050086895A (en) 2005-08-30
PT1567667E (en) 2008-11-04
HK1081598A1 (en) 2006-05-19
HRP20050493A2 (en) 2005-10-31
DK1567667T3 (en) 2009-01-12
UA86582C2 (en) 2009-05-12
EP1567667B1 (en) 2008-10-15
PL376101A1 (en) 2005-12-12
DE60324180D1 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
CY1108730T1 (en) HUNDINGTON DISEASE TREATMENT WITH EPA
NO20042769L (en) Method of showing human papillomavirus mRNA
DE60320007D1 (en) PHENETHANOLAMINE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES
BR0312785A (en) Treatment of Tnf-related disorders (alpha)
ATE406575T1 (en) METHOD FOR DETECTING DRUG SENSITIVITY IN PATIENTS WITH INFLAMMATORY DISEASES
BR0200350A (en) L-amino acid-producing bacterium belonging to the genus escherichia, and method to produce l-amino acid
BR0214329A (en) 1-amino acid producing bacterium, and methods for producing 1-amino acid and lower alpha-1-aspartyl-1-phenyl-alanine lower alkyl ester
WO2001027857A3 (en) Methods for generating databases and databases for identifying polymorphic genetic markers
EA200401365A1 (en) METHODS OF TREATMENT OF ILEUS
WO2005099716A3 (en) Method for analyzing the biological age of a subject
TW200700725A (en) Detection of nucleic acid associated with disease
FR2847262B1 (en) BACTERIA CAPABLE OF PRODUCING L-LYSINE OR L-ARGININE AND PROCESS FOR PRODUCING L-LYSINE OR L-ARGININE USING THE SAME
MX2024013120A (en) Transcriptome analysis for treating inflammation
BRPI0214821B8 (en) method to determine the responsiveness of an individual with a psychotic disorder to treatment with loperidone
BRPI0413562A (en) l-threonine preparation process
ATE531813T1 (en) SYSTEM FOR MONITORING BACTERIAL TUMOR TREATMENT
AU2001245319A1 (en) Methods of treating diseases with activated protein c
BRPI0401947A (en) Method for producing an l-amino acid and bacteria
EA200970590A1 (en) CRTH2 ANTAGONISTS
EP1809307A4 (en) MEDICAL SOLUTION AND METHOD FOR PRODUCTION AND USE
ATE330596T1 (en) USE OF 3-BEZOYLPHENYLACETIC ACID DERIVATIVES FOR THE TREATMENT OF RETINAL DISEASES
NO20045089L (en) Substituted amino alkano phosphonic acids for the treatment of neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other ocular disorders
EA200000740A1 (en) METHOD OF TREATMENT OF THE DISEASE OF CHRONIC PULP OF THE PULMONARY TRACT
ATE392212T1 (en) USE OF A PROTEASOME INHIBITOR TO TREAT FIBROTIC DISEASES
WO2003107545A3 (en) TECHNIQUES FOR IDENTIFYING COMPOUNDS FOR TREATING PATHOLOGICAL CONDITIONS

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application